journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/29134959/targeting-ret-driven-cancers-lessons-from-evolving-preclinical-and-clinical-landscapes
#1
REVIEW
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET rearrangements and mutations have since been identified as actionable drivers of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers. Nevertheless, response rates to RET-directed therapy are modest compared with those achieved using targeted therapies matched to other oncogenic drivers of solid tumours, such as sensitizing EGFR or BRAF(V600E) mutations, or ALK or ROS1 rearrangements...
November 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29134958/immunotherapy-nice-to-see-you-evolving-mhc-i-peptide-presentation
#2
Diana Romero
No abstract text is available yet for this article.
November 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29115304/tumour-heterogeneity-and-resistance-to-cancer-therapies
#3
REVIEW
Ibiayi Dagogo-Jack, Alice T Shaw
Cancer is a dynamic disease. During the course of disease, cancers generally become more heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse collection of cells harbouring distinct molecular signatures with differential levels of sensitivity to treatment. This heterogeneity might result in a non-uniform distribution of genetically distinct tumour-cell subpopulations across and within disease sites (spatial heterogeneity) or temporal variations in the molecular makeup of cancer cells (temporal heterogeneity)...
November 8, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29115303/immunotherapy-nivolumab-induced-alterations-revealed
#4
Peter Sidaway
No abstract text is available yet for this article.
November 8, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29115302/drug-development-for-noncastrate-prostate-cancer-in-a-changed-therapeutic-landscape
#5
Min Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, Herbert A Vargas, Howard I Scher
This corrects the article DOI: 10.1038/nrclinonc.2017.160.
November 8, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29066819/immunotherapy-gain-beyond-injection
#6
Diana Romero
No abstract text is available yet for this article.
October 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29039424/skin-cancer-propranolol-limits-melanoma-recurrence
#7
David Killock
No abstract text is available yet for this article.
October 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29039423/breast-cancer-abemaciclib-effective-in-combination-with-aromatase-inhibition
#8
Peter Sidaway
No abstract text is available yet for this article.
October 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29039422/drug-development-for-noncastrate-prostate-cancer-in-a-changed-therapeutic-landscape
#9
REVIEW
Min Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, Herbert A Vargas, Howard I Scher
The unprecedented progress in the treatment of metastatic castration-resistant prostate cancer is only beginning to be realized in patients with noncastrate disease. This slow progress in part reflects the use of trial objectives focused on time-to-event end points, such as time to metastasis and overall survival, which require long follow-up durations and large sample sizes, and has been further delayed by the use of approved therapies that are effective at the time of progression. Our central hypotheses are that progress can be accelerated, and that outcomes can be improved by shifting trial objectives to response measures occurring early that solely reflect the effects of the treatment...
October 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29039421/haematological-cancer-extended-efs-with-rituximab
#10
Diana Romero
No abstract text is available yet for this article.
October 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28994424/thyroid-cancer-cabozantinib-effective-in-selected-patients
#11
Peter Sidaway
No abstract text is available yet for this article.
October 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28994423/cholangiocarcinoma-evolving-concepts-and-therapeutic-strategies
#12
REVIEW
Sumera Rizvi, Shahid A Khan, Christopher L Hallemeier, Robin K Kelley, Gregory J Gores
Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA...
October 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28994422/lung-cancer-sabr-effective-against-oligometastatic-disease
#13
Peter Sidaway
No abstract text is available yet for this article.
October 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28994421/breast-cancer-lag3-expression-indicates-favourable-outcomes
#14
Peter Sidaway
No abstract text is available yet for this article.
October 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28994420/lung-cancer-dacomitinib-delays-disease-progression
#15
Peter Sidaway
No abstract text is available yet for this article.
October 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28994419/targeted-therapy-ariel3-broad-benefit-of-parp-inhibitors-in-ovarian-cancer
#16
David Killock
No abstract text is available yet for this article.
October 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28975931/patient-reported-outcomes-in-cancer-care-hearing-the-patient-voice-at-greater-volume
#17
REVIEW
Thomas W LeBlanc, Amy P Abernethy
Recording of patient-reported outcomes (PROs) enables direct measurement of the experiences of patients with cancer. In the past decade, the use of PROs has become a prominent topic in health-care innovation; this trend highlights the role of the patient experience as a key measure of health-care quality. Historically, PROs were used solely in the context of research studies, but a growing body of literature supports the feasibility of electronic collection of PROs, yielding reliable data that are sometimes of better quality than clinician-reported data...
October 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28975930/immunotherapy-tisagenlecleucel-the-first-approved-car-t-cell-therapy-implications-for-payers-and-policy-makers
#18
Vinay Prasad
No abstract text is available yet for this article.
October 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28975929/radiomics-the-bridge-between-medical-imaging-and-personalized-medicine
#19
REVIEW
Philippe Lambin, Ralph T H Leijenaar, Timo M Deist, Jurgen Peerlings, Evelyn E C de Jong, Janita van Timmeren, Sebastian Sanduleanu, Ruben T H M Larue, Aniek J G Even, Arthur Jochems, Yvonka van Wijk, Henry Woodruff, Johan van Soest, Tim Lustberg, Erik Roelofs, Wouter van Elmpt, Andre Dekker, Felix M Mottaghy, Joachim E Wildberger, Sean Walsh
Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research. Radiomic analysis exploits sophisticated image analysis tools and the rapid development and validation of medical imaging data that uses image-based signatures for precision diagnosis and treatment, providing a powerful tool in modern medicine...
October 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28948977/therapeutic-targeting-of-p53-all-mutants-are-equal-but-some-mutants-are-more-equal-than-others
#20
REVIEW
Kanaga Sabapathy, David P Lane
TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated gene across all cancer types. The presence of mutant p53 predisposes to cancer development, promotes the survival of cancer cells, and is associated with ineffective therapeutic responses and unfavourable prognoses. Despite these effects, no drug that abrogates the oncogenic functions of mutant p53 has yet been approved for the treatment of cancer. Current investigational therapeutic strategies are mostly aimed at restoring the wild-type activity of mutant p53, based on the assumption that all p53 mutants are functionally equal...
September 26, 2017: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"